##{"id":61189,"date":"2013-01-25T10:27:16","date_gmt":"2013-01-24T23:27:16","guid":{"rendered":"http:\/\/www.fnarena.com\/index.php\/2013\/01\/25\/treasure-chest-pharmaxis-downer-edi-flightcentre-toll\/"},"modified":"2013-01-25T10:27:16","modified_gmt":"2013-01-24T23:27:16","slug":"treasure-chest-pharmaxis-downer-edi-flightcentre-toll","status":"publish","type":"post","link":"https:\/\/staging.fnarena.com\/index.php\/2013\/01\/25\/treasure-chest-pharmaxis-downer-edi-flightcentre-toll\/","title":{"rendered":"Treasure Chest: Pharmaxis, Downer EDI, Flightcentre, Toll"},"content":{"rendered":"

\n\tBy Rudi Filapek-Vandyck<\/span><\/p>\n

\n\tAnalysts are pointing out this morning, local biotech Pharmaxis<\/span> is awaiting a review of its new drug application for Bronchitol<\/span> use in cystic fibrosis sufferers of 6 years and higher in age. An announcement\/decision by the US Pulmonary-Allergy Drugs Advisory Committee (PADAC<\/span>) is scheduled for Wednesday, 30 January (US time) which will be Thursday, January 31 in Australia.<\/p>\n

\n\tThe importance of the event is illustrated by preliminary statements from Credit Suisse and Deutsche Bank this morning, indicating a positive ruling will lead to a valuation increase of respectively 23c<\/span> and 28c<\/span>. This translates into a potential valuation boost of at least 15% – all else being equal.<\/p>\n

\n\tFor more information see today's Australian Broker Call Report on the FNArena<\/span> website or Stock Analysis.<\/p>\n

\n\tIn addition, Morgan Stanley has issued a few "Research Tactical Ideas" today. Two are positive, one negative.<\/p>\n

\n\tFirst idea is that Downer EDI ((EDI)) shares are likely to receive a boost from a positive outlook to be issued together with the upcoming interim report in February. It is for this reason Morgan Stanley thinks the shares will be higher in 30 days' time.<\/p>\n

\n\tSecond idea is that Flight Centre ((FLT<\/span>)) shares will be higher in 60 days from today. This projection is also based upon a positive results release in February.<\/p>\n

\n\tThird idea is that Toll Holdings ((TOL<\/span>)) may well meet market expectations with its own report next month, but the quality shall be low and that will be a disappointment. In this case Morgan Stanley sticks to a relative call in that Toll shares will weaken on a relative comparison with the index.
\n\t <\/p>\n

\n\tFind out why FNArena<\/span> subscribers like the service so much: "Your Feedback (Thank You)<\/a>" – Warning this story contains unashamedly positive feedback on the service provided.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"